Cannabis Industry’s Lobbying Power Outweighs Public Health Concerns on Beacon Hill
As the cannabis industry continues to grow and thrive in Massachusetts, concerns about the impact of its products on young users are being ignored by state regulators and lawmakers. Despite warnings from scientists and advocates, the industry’s lobbying muscle is overpowering efforts to install public health guardrails.
Amy Turncliff, a scientist and activist, has been sounding the alarm about the risks of teen and young adult cannabis use, particularly high-potency cannabis, for years. She cites the majority of patients in addiction treatment centers as being affected by cannabis-related problems, including psychosis, depression, and anxiety.
The cannabis industry’s influence on Beacon Hill is evident in its lobbying efforts. In the last five years, the industry has spent $7.2 million on lobbying, and $409,000 on campaign donations to politicians. This has led to a lack of progress on public health-related bills, including those that would limit THC potency and strengthen warning labels.
State Rep. Marcus Vaughn, who has filed public health-related bills on Beacon Hill, acknowledges the industry’s power and influence. “Some of them carry a lot of weight and a lot of money,” he said.
The Massachusetts Cannabis Control Commission, responsible for regulating the industry, has also been criticized for its lack of interest in public health priorities. Despite having a commissioner with a background in public health, the commission has failed to take action on public awareness campaigns and education about the risks of cannabis use.
Commission Executive Director Travis Ahern and Commissioner Kimberly Roy have defended the commission’s actions, citing limited resources and funding. However, critics argue that the state’s increased revenue from cannabis sales should be used to fund public awareness campaigns and education.
The commission’s close ties to the industry have also raised concerns. Several former commission employees and commissioners have gone on to work for cannabis companies, leading some to question the commission’s independence.
Turncliff’s frustration is evident, as she has been warning policymakers about the risks of cannabis use for years. “I feel like the answer to that is no,” she said, when asked if anyone was listening. “We’re now six years later, and I am unfortunately very confident that there are more cases of cannabis-induced psychosis than there were then.”
As the cannabis industry continues to grow and thrive, it is clear that public health concerns are being ignored. It is time for policymakers and regulators to take action to protect the health and well-being of young people in Massachusetts.
